XOMA Royalty Corp
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation NV
Business Address 2200 POWELL STREET, EMERYVILLE, CA, 94608
Mailing Address 2200 POWELL STREET, EMERYVILLE, CA, 94608
Phone 510-204-7239
Fiscal Year End 1231
EIN 522154066
Financial Overview
FY2025
$101.65M
Cash & Equivalents
$1.53
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| DEF 14A Definitive proxy statement | March 30, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 26, 2026 | View on SEC |
| 10-K Annual financial report | March 18, 2026 | View on SEC |
| 8-K Current report of material events | March 18, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 6, 2026 | View on SEC |
Annual Reports
10-K March 18, 2026
- Achieved robust financial growth in 2023 with 25% revenue increase to $55.0 million and 54% net income growth to $18.5 million.
- Strategically expanded a diversified portfolio of commercial and clinical-stage royalty assets, including key products like Vabysmo and Ovaprene.
Material Events
8-K Other March 2, 2026
High Impact
- Strong preliminary FY2025 revenue of approximately $49-50 million from royalties and milestones.
- Robust cash and restricted funds balance of approximately $133 million as of December 31, 2025.
8-K Acquisition February 9, 2026
High Impact
- XOMA Royalty Corp. acquired Generation Bio Co., marking a strategic shift beyond its traditional royalty business.
- The acquisition provides XOMA with direct ownership and management of high-potential assets, including gene therapy programs and a collaboration with ModernaTX, Inc.
8-K Acquisition December 5, 2025
High Impact
- XOMA Royalty Corp completed a major acquisition of Mural Oncology plc, taking full ownership of the company and its drug development business.
- This acquisition represents a strategic shift for XOMA, moving beyond its traditional royalty collection model to direct involvement in drug development.
Insider Trading
BUY 1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.